Literature DB >> 7711410

Sustained elimination of hepatitis B virus from serum induced in a patient with chronic hepatitis B and advanced human immunodeficiency virus infection.

T Wölfel1, P Schirmacher, J Schlaak, P Knolle, H P Dienes, W Dippold, K H Meyer zum Büschenfelde, G Gerken.   

Abstract

A 48-year-old male patient was admitted with acquired immunodeficiency syndrome (stage III, Centers for Disease Control 1993) and viremic hepatitis B. Blood CD4 count was 15/microliters. Discontinuation of prednisolone, previously prescribed by the patient's family practitioner because of elevated liver enzymes, resulted in severe hepatitis (alanine aminotransferase > 300U/l). Administration of interferon-alpha (9 x 10(6) U s.c. 3 x weekly) was initiated. Serum markers of viral replication disappeared, and aminotransferase levels returned to normal within a few weeks. The patient's serum was found negative for HBsAg after 3 months. Immunohistochemical analysis of liver biopsies before and during interferon therapy showed disappearance of all hepatitis B virus antigens and a marked reduction in inflammatory activity. Hepatitis B virus seroconversion remained stable until the patient died from the syndrome 2 years later. This case shows that in spite of severe HIV-associated immune deficiency with CD4 counts constantly below 100/microliters, interferon-alpha can lead to sustained serological and histological improvement of viremic hepatitis B. Previous administration and discontinuation of cortisone may have helped to reach this effect.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711410     DOI: 10.1007/bf00577750

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  37 in total

1.  Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS.

Authors:  S Vento; G di Perri; R Luzzati; M Cruciani; T Garofano; C Mengoli; E Concia; D Bassetti
Journal:  Lancet       Date:  1989-02-11       Impact factor: 79.321

2.  Treatment of patients with chronic type B hepatitis and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: a pilot study.

Authors:  G Hess; S Rossol; R Voth; G Gerken; G Ramadori; N Drees; K H Meyer zum Büschenfelde
Journal:  Digestion       Date:  1989       Impact factor: 3.216

3.  Severe hepatic failure after ARA-A-prednisolone for chronic type B hepatitis.

Authors:  M Buti; R Esteban; J I Esteban; A Gonzalez; J Guardia
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

4.  Foscarnet therapy in chronic hepatitis B virus E antigen carriers.

Authors:  V G Bain; H M Daniels; A Chanas; G J Alexander; R Williams
Journal:  J Med Virol       Date:  1989-10       Impact factor: 2.327

5.  HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.

Authors:  R Nayersina; P Fowler; S Guilhot; G Missale; A Cerny; H J Schlicht; A Vitiello; R Chesnut; J L Person; A G Redeker; F V Chisari
Journal:  J Immunol       Date:  1993-05-15       Impact factor: 5.422

6.  Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B.

Authors:  C T Mills; E Lee; R Perrillo
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

7.  Discontinuation of immunosuppressive therapy in hepatitis B surface antigen-positive chronic hepatitis: effect on viral replication and on liver cell damage.

Authors:  G Hess; M Manns; T H Hütteroth; K H Meyer zum Büschenfelde
Journal:  Digestion       Date:  1987       Impact factor: 3.216

8.  Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive.

Authors:  D M Novick; P Farci; T S Croxson; M B Taylor; C W Schneebaum; M E Lai; N Bach; R T Senie; A M Gelb; M J Kreek
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

9.  Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection.

Authors:  S C Hadler; F N Judson; P M O'Malley; N L Altman; K Penley; S Buchbinder; C A Schable; P J Coleman; D N Ostrow; D P Francis
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226

Review 10.  Antiviral therapy of chronic hepatitis B: past, present, and future.

Authors:  R P Perrillo
Journal:  J Hepatol       Date:  1993       Impact factor: 25.083

View more
  1 in total

1.  Hepatitis B virus surface antigen seroconversion after pegylated interferon-alpha treatment in an HIV-infected individual with chronic hepatitis B.

Authors:  B Rossetti; C Bianco; A De Luca
Journal:  Infection       Date:  2011-10-15       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.